Document is current
Any future updates will be listed below
-
Authors
Chouhan, Surbhi
Sridaran, Dhivya https://orcid.org/0000-0003-4401-8571
Weimholt, Cody
Luo, Jingqin https://orcid.org/0000-0003-2759-3072
Li, Tiandao https://orcid.org/0000-0003-1650-0555
Hodgson, Myles C.
Santos, Luana N.
Le Sommer, Samantha
Fang, Bin https://orcid.org/0000-0002-7636-1318
Koomen, John M. https://orcid.org/0000-0002-3818-1762
Seeliger, Markus https://orcid.org/0000-0003-0990-1756
Qu, Cheng-Kui https://orcid.org/0000-0002-4256-8652
Yart, Armelle
Kontaridis, Maria I. https://orcid.org/0000-0002-6121-0533
Mahajan, Kiran
Mahajan, Nupam P. https://orcid.org/0000-0002-4150-602X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA227025, 1R01CA273054, 1R01CA276502)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense (W81XWH-21-1-0202)
- License Information
-
More Information
Article History
Received: 5 April 2023
Accepted: 27 June 2024
First Online: 4 July 2024
Competing interests
: Patents “Inhibitors of ACK1/TNK2 Tyrosine Kinase” (patent no. 9,850,216, 10,017,478 and 10,336,734) covers (<i>R</i>)-<b>9b</b> compound. N.P.M. and K.M. are named as inventors. TechnoGenesys has licensed these patents. N.P.M. and K.M. are cofounders of TechnoGenesys Inc., own stocks, and serve as consultant. The remaining authors declare no competing interests.
